China's Innovative Drugs See Surge in Overseas Licensing Deals, H1 2025 Transactions Exceed Full-Year 2024 Total

　　【Pharmaceutical Network Industry DynamicsIn July 2025, Hengrui Pharma reached a $12 billion cooperation agreement with GSK, setting a new record for overseas licensing of innovative drugs in China. Data shows that in the first half of 2025, the total transaction amount of overseas licensing for Chinese innovative drugs reached $60.8 billion, surpassing the $51.9 billion for the entire year of 2024, marking a 36% year-on-year increase. This astonishing growth rate not only reflects the rapid rise of Chinese innovative drugs in the global market but also highlights China's transformation from a participant in the global pharmaceuticals market to a co-builder of its rules.
 

The international journey of China's innovative drugs has not been an overnight success, but rather a long accumulation from quantitative to qualitative change. Zanubrutinib by BeiGene, as the first original Chinese anti-cancer drug approved in the United States, owes its success not only to the 52% investment in R&D but also to the inclusion of data from patients of different ethnicities in its global clinical trial design, laying the foundation for the internationalization of China's innovative drugs. This case demonstrates the deep involvement of Chinese innovative drug companies in the global R&D system and paves the way for subsequent overseas licensing deals.
 

Unlike previous deals, the collaboration between Hengrui Pharma and GSK this time is not a single-product licensing agreement but a platform-based partnership covering 12 drugs. This shift in model reflects a significant increase in the bargaining power of China's innovative drug companies. The $500 million upfront payment and potential $12 billion in milestone payments from GSK not only demonstrate international market recognition of the quality of China's innovative drugs but also signify an elevation in the status of Chinese companies within the global pharmaceutical industry chain.
 

The rapid rise of China's innovative drugs is inseparable from strong policy support. Since the National Medical Products Administration joined the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) in 2017, it has fully adopted and implemented 66 guidelines, promoting the alignment of China's drug regulatory system with international standards. This move has significantly enhanced the recognition of China's innovative drugs in the international market, creating favorable conditions for overseas licensing transactions. Meanwhile, the entry into force of the RCEP agreement has facilitated the access of China's innovative drugs to the ASEAN market, further broadening the channels for going global.
 

Industry insiders believe that China's innovative drugs still have significant room for growth in terms of global market influence. Although China accounts for 35% of the global pipeline for innovative drug development, its share of global sales of innovative drugs is only 3%. This stark contrast not only reflects the insufficient penetration of Chinese innovative drugs in international markets but also highlights the urgent need to enhance brand recognition. Currently, many Chinese innovative pharmaceutical companies are breaking through this bottleneck in various ways. For instance, BeiGene’s 70% revenue from overseas demonstrates the success of its global strategy. As a leader in the global CXO (Contract Research and Manufacturing Organization) sector, Wuxi AppTec's 83% revenue from overseas not only underscores its crucial role in the global pharmaceutical industry chain but also provides support for the internationalization of China's innovative drugs.
 

Notably, the overseas expansion of China's innovative drugs is extending from the oncology field to broader therapeutic areas. The collaboration between Hengrui Pharma and GSK covers multiple fields such as respiratory, autoimmune, and inflammation, reflecting breakthroughs in the diversification of China's innovative drugs across various therapeutic domains. This diversified strategy not only reduces the risk associated with a single field but also lays the foundation for the comprehensive global market development of China's innovative drugs.
 

At the same time, the internationalization process of China's innovative drugs is also facing many challenges. The first is market access barriers caused by cultural differences. How to promote China's innovative drugs in different healthcare systems and cultural contexts is a long-term subject that enterprises need to explore. Secondly, competition in the international market is becoming increasingly fierce, especially in popular fields such as PD-1/L1 inhibitors, where there are already more than 5,000 clinical trials globally. China's innovative drugs need to find differentiated advantages amid fierce competition. In addition, the pricing strategy for China’s innovative drugs in the international market also needs optimization. How to balance reasonable profits while improving drug accessibility is a key issue that Chinese companies need to address. This not only relates to the economic benefits of enterprises but also impacts the voice of China's innovative drugs in global health governance.
 

Looking ahead, the overseas licensing transactions of China's innovative drugs are expected to maintain rapid growth. As more innovative drugs enter the international market, China's share in global pharmaceutical R&D will further increase. The industry predicts that by 2030, the sales revenue of China's innovative drugs in the global market may rise to over 10%, becoming an important pole in the global pharmaceutical market and making significant contributions to improving human health.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.